OPKO Health (STU:XCY) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:XCY OPKO Health Inc STU:XCY
42 GF Score
Price €1.08
GF Value €0.92
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is OPKO Health Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

STU:XCY
42GF Score
OPKO Health Inc STU:XCY
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is OPKO Health (STU:XCY) Overvalued in 2026?

Based on GuruFocus' analysis, OPKO Health stock appears to be overvalued. The current stock price of €1.08 is trading 17.4% above its estimated GF Value™ of €0.92. GuruFocus considers OPKO Health to be Modestly Overvalued.

Key valuation signals for STU:XCY:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €0.92 vs. price of €1.08 (17.4% above fair value)
  • GF Score™: 42/100 with 4 warning signs

No single metric tells the full story. See the STU:XCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OPKO Health Business Description

Address 4400 Biscayne Boulevard, Miami, FL, USA, 33137
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
42GF Score

Get the complete analysis for STU:XCY

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.08
Price
€0.92
GF Value